Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print          Annual reports

Thursday 04 March, 2021

AstraZeneca PLC

Designation of EU home member state

RNS Number : 2345R
AstraZeneca PLC
04 March 2021

4 March 2021 15:00 GMT



Designation of EU home member state for EU securities regulation purposes

Following the exit of the United Kingdom from the European Union,   AstraZeneca PLC (AstraZeneca) announces that it has selected Sweden as its home member state for EU securities regulation purposes pursuant to the Swedish Securities Market Act (Sw. lagen (2007.528) om värdepappersmarknaden).


AstraZeneca will file certain regulatory information with the Swedish Financial Supervisory Authority in accordance with applicable EU and Swedish law. These filings will be in addition to AstraZeneca's continuing disclosure obligations under applicable UK law, including the UK Disclosure Guidance and Transparency Rules. AstraZeneca's status as a UK PLC and the location of its headquarters in the United Kingdom remain unchanged.


AstraZeneca's selection of Sweden as its home member state for EU securities regulation purposes also means that certain continuing notification obligations pursuant to Swedish law will apply to dealings or interests in AstraZeneca securities in addition to the existing obligations under the UK Disclosure Guidance and Transparency Rules. These include notifications as soon as holdings of financial instruments or short positions reach, exceed or go below certain thresholds. AstraZeneca recommends its shareholders to inform themselves about the notification obligations under Swedish law and to consult with their legal advisers in case of any questions.



AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @ AstraZeneca .


For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Additional information

This information is information that AstraZeneca PLC is obliged to make public pursuant to the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact persons set out above, at 15:00 on 4 March 2021.


Adrian Kemp
Company Secretary

AstraZeneca PLC



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t